A5035165984- Dialysis and Renal Disease Management
- Blood Pressure and Hypertension Studies
- Chronic Kidney Disease and Diabetes
- Central Venous Catheters and Hemodialysis
- Renal Diseases and Glomerulopathies
- Health Systems, Economic Evaluations, Quality of Life
- Vascular Procedures and Complications
- Parathyroid Disorders and Treatments
- Sodium Intake and Health
- Advanced MRI Techniques and Applications
- Renal function and acid-base balance
- Magnesium in Health and Disease
- Cardiovascular Health and Disease Prevention
- MRI in cancer diagnosis
- Diet and metabolism studies
- Liver Disease Diagnosis and Treatment
- Acute Kidney Injury Research
- Heart Failure Treatment and Management
- Vasculitis and related conditions
- Health disparities and outcomes
- Advanced Neuroimaging Techniques and Applications
- Renal and Vascular Pathologies
- Restless Legs Syndrome Research
- Vascular anomalies and interventions
- Potassium and Related Disorders
Cleveland Clinic
2016-2025
Cleveland Clinic Lerner College of Medicine
2019-2025
Case Western Reserve University
2019-2025
Boston University
2015-2016
Boston Medical Center
2015
University Medical Center
2015
Louisiana State University Health Sciences Center Shreveport
2015
Quantitative BioSciences
1986-2011
Harlem Hospital Center
2008
University of Michigan
2004-2008
<h3>Context</h3>The arteriovenous fistula is the preferred type of vascular access for hemodialysis because lower thrombosis and infection rates health care expenditures compared with synthetic grafts or central venous catheters. Early failure fistulas due to inadequate maturation a barrier increasing prevalence among patients treated hemodialysis. Small, inconclusive trials have suggested that antiplatelet agents may reduce new fistulas.<h3>Objective</h3>To determine whether clopidogrel...
In observational studies, the relationship between blood pressure and end-stage renal disease (ESRD) is direct progressive. The burden of hypertension-related chronic kidney ESRD especially high among black patients. Yet few trials have tested whether intensive blood-pressure control retards progression
Arteriovenous graft stenosis leading to thrombosis is a major cause of complications in patients undergoing hemodialysis. Procedural interventions may restore patency but are costly. Although there no proven pharmacologic therapy, dipyridamole be promising because its known vascular antiproliferative activity.We conducted randomized, double-blind, placebo-controlled trial extended-release dipyridamole, at dose 200 mg, and aspirin, 25 given twice daily after the placement new arteriovenous...
Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal models similar to primary FSGS, and one recent study demonstrated elevated levels serum suPAR patients with the disease. Here, we analyzed circulating two cohorts children adults biopsy-proven FSGS: 70 from North America–based FSGS clinical trial (CT) 94 PodoNet, Europe-based consortium studying steroid-resistant nephrotic syndrome. Circulating were 84.3% 55.3% CT PodoNet cohorts, respectively, compared 6%...
ABSTRACT. Infection is the second most common cause of death among hemodialysis patients. A predefined secondary aim HEMO study was to determine if dialysis dose or flux reduced infection-related deaths hospitalizations. The effects dose, membrane, and other clinical parameters on first hospitalizations were analyzed using Cox regression analysis. Among 1846 randomized patients (mean age, 58 yr; 56% female; 63% black; 45% with diabetes), there 871 deaths, which 201 (23%) due infection. There...
Frequent hemodialysis requires using the vascular access more often than with conventional hemodialysis, but whether this increases risk for access-related complications is unknown. In two separate trials, we randomly assigned 245 patients to receive in-center daily (6 days per week) or (3 and 87 home nocturnal nights 12 months. The primary outcome was time first event (repair, loss, hospitalization). Secondary outcomes were all repairs losses. Daily Trial, 77 (31%) of had a event: 33 15...
Summary Background and objectives FSGS histologic variants have correlated with outcomes in retrospective studies. The Clinical Trial provided a unique opportunity to study the clinical impact of well defined prospective cohort steroid-resistant primary FSGS. Design, setting, participants, & measurements Renal biopsies 138 participants aged 2–38 years enrolled from 2004 2008 were analyzed using Columbia classification by core pathologists. This assessed distribution examined their biopsy...
ObjectiveEarly thrombosis (ET) contributes to autogenous arteriovenous fistula (AVF) failure. We studied patients undergoing AVF placement in the Hemodialysis Fistula Maturation Study, a prospective, observational cohort study, using nested case-control analysis identify preoperative and intraoperative predictors of ET.MethodsET cases were compared with controls, who matched for gender, age, diabetes, dialysis status, surgeon volume. ET was defined as diagnosed by physical examination or...
Genetic variants in apolipoprotein L1 (APOL1) confer risk for kidney disease. We sought to better define the phenotype of APOL1-associated nephropathy. The FSGS Clinical Trial involved 138 children and young adults who were randomized cyclosporin or mycophenolate mofetil plus pulse oral dexamethasone with a primary outcome proteinuria remission. DNA was available from 94 subjects genotyped APOL1 renal variants, two alleles comprising genotype. Two present 27 subjects, whom four did not...
Significance Statement Higher serum phosphate and fibroblast growth factor-23 (FGF23) levels are potential modifiable risk factors to prevent cardiovascular disease in CKD. Studies evaluating intestinal binders found modest efficacy for lowering FGF23 during short-term follow-up In their randomized, placebo-controlled trial 205 participants with stage 3b/4 CKD, the authors evaluated effects of nicotinamide (an inhibitor active transport), binder lanthanum carbonate, or both, versus placebo...
The incidence and factors associated with hyperkalemia in patients chronic kidney disease (CKD) treated angiotensin converting enzyme inhibitors (ACEIs) other antihypertensive drugs was investigated using the African American Study of Kidney Disease Hypertension (AASK) database.A total 1094 nondiabetic adults hypertensive CKD (glomerular filtration rate [GFR], 20-65 mL/min/1.73 m(2)) were followed for 3.0 to 6.4 years AASK trial. Participants randomly assigned ACEI, beta-blocker (BB), or...
Abnormal ambulatory BP (ABP) profiles are commonplace in CKD, yet the prognostic value of ABP for renal and cardiovascular outcomes is uncertain. This study assessed relationship baseline with CKD progression subsequent to determine beyond that clinic measurements.Between 2002 2003, 617 African Americans hypertensive treated a goal <130/80 mmHg were enrolled this prospective, observational study. Participants followed median 5 years. Primary outcome was composite doubling serum creatinine,...
Abstract Hypertension is a common complication of chronic kidney disease and persists among most patients with end‐stage renal despite the provision conventional thrice weekly hemodialysis ( HD ). We analyzed effects frequent on blood pressure in randomized controlled F requent H emodialysis N etwork trials. The daily trial 245 to 12 months 6× (“frequent”) vs. 3× (“conventional”) in‐center hemodialysis; nocturnal 87 predominantly home‐based hemodialysis. In trial, compared , 2 lowered...